Zydus gets USFDA nod for drug trials to treat chemotherapy-induced anemia

Topics Zydus Cadila | USFDA

Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to initiate clinical trials for its drug 'Desidustat' in treatment of chemotherapy-induced anemia (CIA).

Desidustat is a novel drug which is also currently undergoing phase-III trials for treating anemia in chronic kidney disease patients and phase-II studies for management of COVID-19 patients.

In a regulatory filing, Zydus Cadila said it has received approval from the US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in CIA.

Zydus Cadila Chairman Pankaj R Patel said CIA is a serious unmet medical need and there is a need for novel therapies to address this condition.

Desidustat has been specifically designed to improve haemoglobin, reduce hepcidin and thereby treat anemia, he added.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 369.95 apiece on BSE, 0.91 per cent higher against their previous close.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel